Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs

• Main Authors: Alen Brkic (Author), Andreas P. Diamantopoulos (Author), Espen Andre Haavardsholm (Author), Bjørg Tilde Svanes Fevang (Author), Lene Kristin Brekke (Author), Liz Loli (Author), Camilla Zettel (Author), Erik Rødevand (Author), Gunnstein Bakland (Author), Pawel Mielnik (Author), Glenn Haugeberg (Author)
• Format: Book
• Published: BMC, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in Norwegian rheumatoid arthritis (RA)...